Intranasal Ketamine Treatment in an Adult With Autism Spectrum Disorder

Logan K. Wink, MD; Anne M. O†Melia, MD; Rebecca C. Shaffer, PsyD; Ernest Pedapati, MD; Katherine Friedmann, RN; Tori Schaefer, PhD; and Craig A. Erickson, MD

Published: August 26, 2014

Article Abstract

‘ ‹Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Ketamine, a noncompetitive antagonist at the N-methyl-d-aspartate glutamate receptor, has been demonstrated in controlled clinical trials to rapidly decrease symptoms of depression in adults via intravenous infusion and has demonstrated promising results in an uncontrolled trial of intranasal infusion in adolescents with bipolar disorder. Other glutamatergic modulators, including d-cycloserine, amantadine, and memantine, have been the focus of drug development targeting core social impairment in autism spectrum disorder (ASD). However, to date, there have been no reports of ketamine treatment in individuals with ASD.

Volume: 75

Quick Links: Depression (MDD) , Suicide

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Insights

LAI Antipsychotics in Schizophrenia: Long-term Outcomes of Early Use

Using data from the...

Read More...